We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App





Mindray Demonstrates Latest IVD Innovations at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 11 Apr 2022

Mindray (Shenzhen, China) displayed its latest laboratory innovations at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, EUROMEDLAB 2022, in Munich, Germany. More...

EUROMEDLAB is the most influential platform in Europe where new ideas and technologies in laboratory diagnostics are shared and showcased. Mindray’s wide range of IVD products attracted customers from Europe and other parts of the world.

At EUROMEDLAB 2022, Mindray displayed the new MC-80 automated digital cell morphology analyzer that is taking digital morphology analysis to the next level by delivering clearer images which are able to capture abnormalities in more detail. With advanced algorithms, the analyzer enables better identification of different cells with high throughput, resulting in greater productivity. Its high-performance objective and advanced image sensor offer ultra resolution images to reappear the real view under the microscope. The MC-80 has an industry-leading throughput of 60 slides per hour and features a solid rock hyper-stable anti-shake system. Aerospace materials and cutting-edge high-frequency exposure algorithm are integrated to eliminate blurred images.

Mindray also demonstrated the new CAL 8000 New Generation Cellular Analysis Line which marks the company’s expertise and innovative power in hematology area for large-scale laboratories. It has higher throughput per square meter, upgraded labXpert Data Management Software, flexible layout design options, and other advanced functionalities. Combining Mindray’s new MC-80 digital cell morphology analyzer, the CAL 8000 is taking hematology analysis automation to the next level. The touch screen is the “brain” of CAL 8000. It optimizes the distribution of workload between each analyzer unit and decides which sample requires a blood smear. It displays the status of each analyzer or SC-120 installed on CAL 8000 as well as the volume of balance reagent. This intuitive software can tell the users all necessary information of CAL 8000 at any given time. Consequently, users spend less time operating CAL 8000 and can arrange their working schedule better. Additionally, Mindray exhibited its M6000 laboratory automation system which can empower ultra high volume laboratories with high processing speed, less hands-on time, great cost efficiency and standardized analytical quality.

Related Links:
Mindray 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
All-in-One Molecular System
AIO M160
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.